CLINICAL TRIALS PROFILE FOR TEPEZZA
✉ Email this page to a colleague
All Clinical Trials for TEPEZZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04583735 ↗ | A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease | Recruiting | Horizon Therapeutics USA, Inc. | Phase 4 | 2021-09-02 | The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will not be infused). |
| NCT05002998 ↗ | TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study | Not yet recruiting | Horizon Therapeutics USA, Inc. | Phase 4 | 2021-08-01 | This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants. This international, Phase 3b/4 trial is being conducted to fulfill an FDA post-marketing requirement for a descriptive trial to evaluate the safety, efficacy and need for re-treatment of 3 different teprotumumab treatment durations for TED. In addition, serum samples from participants with a Baseline Clinical Activity Score (CAS) ≥3 will be evaluated for biomarkers of disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TEPEZZA
Condition Name
Clinical Trial Locations for TEPEZZA
Trials by Country
Clinical Trial Progress for TEPEZZA
Clinical Trial Phase
Clinical Trial Sponsors for TEPEZZA
Sponsor Name
